The eFIT system is designed to address challenges in the biopharmaceutical industry by providing a chemical-free solution for pathogen inactivation.

eFIT significantly increases efficiency by accelerating production cycles compared to conventional chemical inactivation methods. This advancement allows for faster vaccine production, meeting the growing demands of the biopharmaceutical industry and enhancing the overall safety of the production process by eliminating the need for toxic chemicals such as formaldehyde. This chemical-free approach reduces potential health risks for workers and ensures a safer manufacturing environment. The system also improves the quality of vaccines by maintaining the integrity of surface proteins. This preservation is crucial for producing more effective vaccines that can elicit a robust immune response. Furthermore, the eFIT system offers remarkable versatility, making it suitable for inactivating various pathogens. Its adaptability allows it to be applied in multiple biopharmaceutical processes, providing a flexible solution for diverse manufacturing needs.

Dr. Andrea Traube, Chief Executive Officer at KyooBe Tech, commented, "The eFIT system represents a significant advancement in vaccine manufacturing. It not only enhances production speed and safety but also significantly improves product quality, setting a new standard in the industry."
The launch of eFIT follows extensive pilot testing and validation at an industrial scale. KyooBe Tech has optimized the system for commercial use, reducing its footprint while increasing production capacity to meet market demands. "We are thrilled to introduce eFIT to the market," said Daniel Becker, Head of Business Development eFIT at KyooBe Tech. "This technology has the potential to revolutionize vaccine manufacturing, making it faster, safer, and more cost-effective."